{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T17:25:58Z","timestamp":1648920358623},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T00:00:00Z","timestamp":1485216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s12020-017-1235-3","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T05:53:07Z","timestamp":1485237187000},"page":"179-182","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells"],"prefix":"10.1007","volume":"57","author":[{"given":"Giovanni","family":"Tulipano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Faggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Spinello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,24]]},"reference":[{"key":"1235_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12020-013-0129-2","volume":"47","author":"A Colao","year":"2014","unstructured":"A. Colao, M. Boscaro, D. Ferone, F.F. Casanueva, Managing Cushing\u2019s disease: the state of the art. Endocrine 47, 9\u201320 (2014)","journal-title":"Endocrine"},{"key":"1235_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","volume":"34","author":"M Theodoropoulou","year":"2013","unstructured":"M. Theodoropoulou, G. Stalla, Somatostatin receptors: from signalling to clinical practice. Front. Neuroendocrinol. 34, 228\u2013252 (2013)","journal-title":"Front. Neuroendocrinol."},{"key":"1235_CR3","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1517\/13543784.2014.942728","volume":"23","author":"A Giustina","year":"2014","unstructured":"A. Giustina, G. Mazziotti, F. Maffrezzoni, V. Amoroso, A. Berruti, Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opin. Investig. Drugs 23, 1619\u20131635 (2014)","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"1235_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/me.2009-0321","volume":"24","author":"R Cescato","year":"2010","unstructured":"R. Cescato, K.A. Loesch, B. Waser, H.R. Macke, J.E. Rivier, J.C. Reubi, A. Schonbrunn, Agonist-biased signalling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signalling pathways. Mol. Endocrinol. 24, 240\u2013249 (2010)","journal-title":"Mol. Endocrinol."},{"key":"1235_CR5","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1210\/me.2009-0315","volume":"24","author":"F Poll","year":"2010","unstructured":"F. Poll, D. Lehman, S. Illing, M. Ginj, S. Jacobs, A. Lupp, R. Stumm, S. Schulz, Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol. Endocrinol. 24, 436\u2013446 (2010)","journal-title":"Mol. Endocrinol."},{"key":"1235_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Y.C. Patel, Somatostatin and its receptor family. Front. Neuroendocrinol. 20, 157\u2013198 (1999)","journal-title":"Front. Neuroendocrinol."},{"key":"1235_CR7","first-page":"841","volume":"1","author":"M Peng","year":"1998","unstructured":"M. Peng, L. Conforto, D.E. Millhorn, Expression of somatostatin receptor genes and acetylcholine receptor development in rat skeletal muscle during postnatal development. Int. J. Mol. Med. 1, 841\u2013848 (1998)","journal-title":"Int. J. Mol. Med."},{"key":"1235_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jne.12231","volume":"27","author":"G Tulipano","year":"2015","unstructured":"G. Tulipano, L. Faggi, A. Cacciamali, M. Spinello, D. Cocchi, A. Giustina, Role of AMP- activated protein kinase activators in antiproliferative multi-drug pituitary tumor therapy: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumor cells. J. Neuroendocrinol. 27, 20\u201332 (2015)","journal-title":"J. Neuroendocrinol."},{"key":"1235_CR9","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1002\/cncr.26011","volume":"117","author":"B Svejda","year":"2011","unstructured":"B. Svejda, M. Kidd, A. Kazberouk, B. Lawrence, R. Pfragner, I.M. Modlin, Limitations in small intestinal neuroendocrine tumor therapy by mTOR kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1\/2 and AKT. Cancer 117, 4141\u20134154 (2011)","journal-title":"Cancer"},{"key":"1235_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/jcb.21833","volume":"105","author":"M Menconi","year":"2008","unstructured":"M. Menconi, P. Gonnella, V. Petkova, S. Lecker, P.-O. Hasselgren, Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes. J. Cell Biochem. 105, 353\u2013364 (2008)","journal-title":"J. Cell Biochem."},{"key":"1235_CR11","doi-asserted-by":"publisher","first-page":"21374","DOI":"10.1074\/jbc.M313522200","volume":"289","author":"G Tulipano","year":"2004","unstructured":"G. Tulipano, R. Stumm, M. Pfeiffer, H.J. Kreienkamp, V. Hollt, S. Schulz, Differential trafficking and endosomal sorting of somatostatin receptor subtypes. J. Biol. Chem. 289, 21374\u201321382 (2004)","journal-title":"J. Biol. Chem."},{"key":"1235_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.regpep.2004.07.027","volume":"125","author":"G Tulipano","year":"2005","unstructured":"G. Tulipano, E. Rossi, M.D. Culler, J.E. Taylor, S. Bonadonna, V. Locatelli, D. Cocchi, A. Giustina, The somatostatin subtype 2 receptor antagonist, BIM-23627, improbe the catabolic effect induced by long-term glucocorticoid treatment in the rat. Regul. Pept. 125, 85\u201392 (2005)","journal-title":"Regul. Pept."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-017-1235-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1235-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1235-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T09:41:00Z","timestamp":1567762860000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-017-1235-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,24]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1007\/s12020-017-1235-3","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,24]]},"assertion":[{"value":"30 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G.T., L.F., declare that they have no conflict of interest. M.S. is employed by Novartis Farma SpA (Origgio, Italy). A.G. has received consulting and lecture fees form Ipsen, Novartis and Pfeizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}